Unicycive Therapeutics Announces Upcoming Poster Presentations
Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a biotechnology firm dedicated to developing treatments for kidney diseases, has revealed that it will present three posters featuring their product candidates at the American Society of Nephrology (ASN) Kidney Week 2024. This important event, which serves as a major platform for sharing advancements in nephrology, is scheduled to take place from October 24-27, 2024.
Key Highlights of the Presentations
The posters will showcase significant research involving oxylanthanum carbonate (OLC) and UNI-494, both of which have attracted considerable attention within the medical community. Shalabh Gupta, MD, the Chief Executive Officer of Unicycive, expressed enthusiasm about the opportunity to present at this prestigious meeting in the nephrology field.
Details Regarding the Poster Presentations
Here are the titles and authors that will be highlighted at the event:
- Title: Intravenous UNI-494 Slows the Progression or Halts/Reverses Acute Kidney Injury When Administered After Ischemia/Reperfusion in Rats
- Lead Author: Satya Medicherla, Ph.D., Vice President, Preclinical Pharmacology, Unicycive
- Session Title: AKI: Mechanisms
- Poster Board: #FR-PO155
- Date/Time: October 25, 2024, from 10:00 a.m. – 12:00 p.m. PT
- Title: Combination Oxylanthanum Carbonate and Tenapanor Lowers Urinary Phosphate Excretion in Rat
- Lead Author: Satya Medicherla, Ph.D., Vice President, Preclinical Pharmacology, Unicycive
- Session Title: CKD-MBD: Basic and Translational
- Poster Board: #SA-PO243
- Date/Time: October 26, 2024, from 10:00 a.m. – 12:00 p.m. PT
- Title: UNI-494 Phase I Safety, Tolerability, and Pharmacokinetics
- Lead Author: Guru Reddy, Ph.D., Vice President of Preclinical R&D, Unicycive
- Session Title: AKI: Clinical, Outcomes, and Trials - Management
- Poster Board: #SA-PO036
- Date/Time: October 26, 2024, from 10:00 a.m. – 12:00 p.m. PT
About Oxylanthanum Carbonate
Oxylanthanum carbonate is an innovative phosphate binding agent that employs advanced nanoparticle technology to manage hyperphosphatemia in patients with chronic kidney disease (CKD). With over forty patents granted worldwide, OLC has the potential to offer benefits over existing treatments by reducing the number and size of pills needed for effective patient management. Nephrologists have noted that addressing the pill burden is a critical unmet need in the treatment of hyperphosphatemia, which can enhance patient adherence.
Market Potential and Development Pathway
The market for hyperphosphatemia treatment is projected to exceed $2.5 billion, with a substantial share coming from the United States. Unicycive is actively seeking FDA approval for OLC through the 505(b)(2) regulatory pathway, having completed several studies, including a pivotal clinical trial that yielded positive results regarding tolerability and efficacy.
Understanding Hyperphosphatemia
Hyperphosphatemia is a prevalent complication among patients with End Stage Renal Disease (ESRD). If left untreated, it can result in severe health issues, including cardiovascular disease and bone health complications. Effective management of hyperphosphatemia centers on lowering serum phosphate levels through dietary restrictions and the use of phosphate binding medications, which facilitate the elimination of phosphate.
UNI-494: An Innovative Therapeutic Candidate
UNI-494 is a cutting-edge therapeutic candidate that functions as a selective activator of ATP-sensitive mitochondrial potassium channels. Currently in clinical development, it targets acute kidney injury and related conditions. Following the completion of a Phase 1 safety study, results are expected soon. Additionally, UNI-494 has received orphan drug designation from the FDA for its potential to prevent Delayed Graft Function (DGF) in kidney transplant patients.
Acute Kidney Injury and Delayed Graft Function Explained
Acute kidney injury (AKI) is marked by a sudden decline in kidney function, often triggered by factors such as sepsis or ischemia. Delayed Graft Function (DGF) is a specific type of AKI that can occur after kidney transplantation and may necessitate dialysis. Ischemia-Reperfusion Injury (IRI) plays a significant role in the development of AKI in this context. Research is ongoing into strategies like ischemic preconditioning to improve renal protection.
About Unicycive Therapeutics
Unicycive Therapeutics is committed to developing groundbreaking therapies for kidney diseases. Their leading candidate, OLC, aims to tackle hyperphosphatemia, while UNI-494 offers a new strategy for addressing acute kidney injury. Those interested in learning more can reach out to the company for additional information.
Contact Information:
ir@unicycive.com
(650) 543-5470
Frequently Asked Questions
What is the purpose of Unicycive's poster presentations?
The presentations are designed to share research findings on OLC and UNI-494, showcasing innovations in the treatment of kidney diseases.
What are the main products being highlighted at ASN Kidney Week 2024?
Unicycive will feature oxylanthanum carbonate (OLC) and UNI-494 during the event.
How does oxylanthanum carbonate benefit patients?
OLC helps reduce the pill burden for patients with CKD, which can lead to improved adherence to treatment regimens.
What is UNI-494's mechanism of action?
UNI-494 works by activating mitochondrial potassium channels to help restore kidney function during episodes of AKI.
How can one obtain more information about Unicycive Therapeutics?
For further details, interested individuals can contact Unicycive Therapeutics directly through their investor relations email.
